Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free ELOX Stock Alerts

Eloxx Pharmaceuticals (ELOX) Competitors

Eloxx Pharmaceuticals logo
$0.36 0.00 (0.00%)
As of 05/22/2026 03:00 PM Eastern
Compare

ELOX vs. SCPS, VAXX, ORGS, TRVN, and NAVB

Should you buy Eloxx Pharmaceuticals stock or one of its competitors? MarketBeat compares Eloxx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eloxx Pharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Orgenesis (ORGS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Eloxx Pharmaceuticals compare to Scopus BioPharma?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Scopus BioPharma. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Eloxx Pharmaceuticals has a beta of -1907.33, meaning that its stock price is 190,833% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Vaxxinity. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 1 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaxxinity
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eloxx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A N/A N/A
Eloxx Pharmaceuticals N/A N/A N/A

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxxinityN/AN/A-$56.93M-$0.45N/A
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A

Vaxxinity has a beta of -74.37, indicating that its share price is 7,537% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its share price is 190,833% less volatile than the broader market.

Summary

Vaxxinity beats Eloxx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Orgenesis?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Orgenesis. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Orgenesis Neutral

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Orgenesis. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Orgenesis -3,827.81%N/A -130.18%

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eloxx Pharmaceuticals has a beta of -1907.33, suggesting that its share price is 190,833% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Orgenesis on 6 of the 10 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Trevena?

Trevena (NASDAQ:TRVN) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Trevena. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Trevena. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Eloxx Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Eloxx Pharmaceuticals N/A N/A N/A

13.6% of Trevena shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Trevena has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its stock price is 190,833% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Trevena on 5 of the 9 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Navidea Biopharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Eloxx Pharmaceuticals has a beta of -1907.33, meaning that its stock price is 190,833% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Eloxx Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Get Eloxx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELOX vs. The Competition

Export
MetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.83M$309.61M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E Ratio-0.26N/A21.0025.66
Price / SalesN/A189.70562.1886.31
Price / CashN/A22.4443.4956.67
Price / BookN/A4.7710.417.14
Net Income-$36.06M-$132.96M$3.57B$335.98M
7 Day PerformanceN/A2.45%6.40%4.11%
1 Month Performance176.92%31.23%3.54%2.52%
1 Year PerformanceN/A77.59%34.14%35.04%

Eloxx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELOX
Eloxx Pharmaceuticals
N/A$0.36
flat		N/AN/A$1.83MN/AN/A30
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$25KN/AN/A9
VAXX
Vaxxinity
N/A$0.00
flat		N/A+0.0%$13KN/AN/A90
ORGS
Orgenesis
N/A$0.00
-95.3%		N/A-68.9%$11K$662KN/A150
TRVN
Trevena
N/A$0.01
flat		N/A-99.0%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ELOX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel